Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

by Mehreen S Datoo et al

 Promising Results for New Malaria Vaccine in African Children A phase 3 clinical trial published in The Lancet provides strong evidence that a new malaria vaccine, R21/Matrix-M, is highly efficacious and safe in African children. The randomized controlled trial was conducted at sites across four sub-Saharan African countries from 2021-2022. Nearly 5000 children aged 5-36 months received three doses of the R21/Matrix-M vaccine or a control rabies vaccine.

26th February 2024 • comment

Integrating vaccines and monoclonal antibodies into malaria prevention

by Terrie E. Taylor & Faith Osier
28th January 2024 • comment

Malaria in 2022: Increasing challenges, cautious optimism

by Prasanna Jagannathan, Abel Kakuru
23rd November 2023 • comment